In The Know-March 2026

March 2026

Pdf Summary

Ed’s List (March 2026) highlights notable gynecologic oncology publications spanning ovarian, endometrial, and cervical cancer prevention, biology, diagnostics, survivorship, and emerging therapies.

Several items focus on ovarian cancer diagnosis and outcomes. A JAMA Network Open cohort study (North Carolina registry-linked claims; n=2,359) found a <strong>U-shaped relationship</strong> between diagnostic interval and mortality: very short and very long time-to-diagnosis were associated with worse survival, consistent with the <strong>“wait time paradox”</strong> (sicker patients are diagnosed faster yet do worse), suggesting linear models may mask benefits of earlier detection. Long-term outcomes in high-grade serous ovarian cancer (single-center, 1991–2022; n=2,074) showed excess mortality declines with time; by ~7 event-free years the standardized mortality ratio approximated the general population, emphasizing individualized survivorship follow-up.

Mechanistic and translational ovarian studies include: multimodal imaging demonstrating <strong>lysosomal sequestration</strong> creates a reservoir for some PARP inhibitors (rucaparib/niraparib but not olaparib), contributing to heterogeneous intratumoral drug distribution and response; and integrated spatial multiomics of <strong>serous tubal intraepithelial carcinoma (STIC)</strong> identifying four precursor subtypes (proliferative, immunoreactive, mixed, dormant) that may influence progression risk and early detection strategies.

Therapeutics and biomarkers are also featured. The OLAPCO trial tested olaparib alone or combined with ATR (ceralasertib) or AKT (capivasertib) in genomically selected tumors; overall response rates were low, arguing DDR alterations are not reliably actionable in a histology-agnostic way with these combinations. A Cell Reports study links <strong>FAK inhibition</strong> to omega-3–rich exosomes that reprogram peritoneal macrophages (CXCL13) and enhance response to combination therapy including anti-TIGIT.

Prevention/clinical guidance includes an ESGO consensus statement supporting <strong>opportunistic salpingectomy</strong> to reduce future tubo-ovarian carcinoma risk with minimal short-term ovarian impact, and a JAMA Internal Medicine review outlining structured <strong>post-treatment surveillance after CIN2/3</strong>. Endometrial cancer updates include worse survival associated with <strong>isolated tumor cells</strong> in otherwise low-risk disease (NCDB analysis) and a Clin Cancer Research report finding <strong>ESR1 mutations</strong> are uncommon overall but enriched in metastatic NSMP low-grade endometrioid tumors—relevant for aromatase inhibitor use.

Keywords

gynecologic oncology

ovarian cancer diagnosis interval

wait time paradox

high-grade serous ovarian cancer survivorship

PARP inhibitor lysosomal sequestration

serous tubal intraepithelial carcinoma (STIC) subtypes

olaparib combination therapy (ATR/AKT inhibitors)

FAK inhibition and omega-3 exosomes

opportunistic salpingectomy prevention

post-treatment surveillance after CIN2/3